{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:47:46Z","timestamp":1793368066576,"version":"4.5.0"},"reference-count":115,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T00:00:00Z","timestamp":1646265600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.anai.2022.02.021","type":"journal-article","created":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T20:05:24Z","timestamp":1646683524000},"page":"169-180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":120,"title":["Allergic and eosinophilic asthma in the era of biomarkers and biologics: similarities, differences and misconceptions"],"prefix":"10.1016","volume":"129","author":[{"given":"John","family":"Oppenheimer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia C.L.","family":"Hoyte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanda","family":"Phipatanakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared","family":"Silver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Howarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Njira L.","family":"Lugogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.anai.2022.02.021_bib0001","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.anai.2020.12.015","article-title":"Real-world evidence: patient views on asthma in respiratory specialist clinics in America","volume":"126","author":"Oppenheimer","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/j.anai.2022.02.021_bib0002","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.anai.2022.02.021_bib0003","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1164\/rccm.201901-0016OC","article-title":"The projected economic and health burden of uncontrolled asthma in the United States","volume":"200","author":"Yaghoubi","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.anai.2022.02.021_bib0004","first-page":"85","article-title":"Clinical and economic burden of elevated blood eosinophils in patients with and without uncontrolled asthma","volume":"23","author":"Casciano","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"issue":"2","key":"10.1016\/j.anai.2022.02.021_bib0005","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.anai.2020.04.024","article-title":"Effect of clinically significant thresholds of eosinophil elevation on health care resource use in asthma","volume":"125","author":"Dotiwala","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"11","key":"10.1016\/j.anai.2022.02.021_bib0006","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S2213-2600(15)00367-7","article-title":"Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study","volume":"3","author":"Price","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.anai.2022.02.021_bib0007","first-page":"44","article-title":"Progression to uncontrolled severe asthma: a novel risk equation","volume":"23","author":"Casciano","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"issue":"10","key":"10.1016\/j.anai.2022.02.021_bib0008","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1164\/rccm.201604-0866OC","article-title":"A severe asthma disease signature from gene expression profiling of peripheral blood from U-BIOPRED cohorts","volume":"195","author":"Bigler","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.anai.2022.02.021_bib0009","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/nm.2678","article-title":"Asthma phenotypes: the evolution from clinical to molecular approaches","volume":"18","author":"Wenzel","year":"2012","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.anai.2022.02.021_bib0010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41390-020-01231-6","article-title":"Defining pediatric asthma: phenotypes to endotypes and beyond","volume":"90","author":"Conrad","year":"2021","journal-title":"Pediatr Res"},{"issue":"2","key":"10.1016\/j.anai.2022.02.021_bib0011","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1183\/13993003.01359-2015","article-title":"Treatable traits: toward precision medicine of chronic airway diseases","volume":"47","author":"Agusti","year":"2016","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.anai.2022.02.021_bib0012","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12016-018-8712-1","article-title":"Understanding asthma phenotypes, endotypes, and mechanisms of disease","volume":"56","author":"Kuruvilla","year":"2019","journal-title":"Clin Rev Allergy Immunol"},{"issue":"4","key":"10.1016\/j.anai.2022.02.021_bib0013","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00936-2018","article-title":"Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma","volume":"52","author":"Bleecker","year":"2018","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.anai.2022.02.021_bib0014","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jaip.2018.04.043","article-title":"Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, a prospective real-world study","volume":"7","author":"Casale","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.anai.2022.02.021_bib0015","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jaip.2019.08.050","article-title":"Dupilumab efficacy in patients with uncontrolled, moderate-to-severe allergic asthma","volume":"8","author":"Corren","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"10.1016\/j.anai.2022.02.021_bib0016","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","article-title":"Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies","volume":"4","author":"Ortega","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.anai.2022.02.021_bib0017","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/all.14425","article-title":"EAACI biologicals guidelines-recommendations for severe asthma","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2022.02.021_bib0018","unstructured":"Global Initiative for Asthma. Global strategy for asthma management and prevention. Available at: www.ginasthma.org. Accessed May 11, 2021."},{"issue":"4","key":"10.1016\/j.anai.2022.02.021_bib0019","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/cea.13790","article-title":"Overlap of allergic, eosinophilic and type 2 inflammatory subtypes in moderate-to-severe asthma","volume":"51","author":"Chen","year":"2021","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.anai.2022.02.021_bib0020","first-page":"PA1096","article-title":"Patients with allergic and eosinophilic asthma in the German severe asthma registry","volume":"46","author":"Holstege","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.anai.2022.02.021_bib0021","first-page":"PA2609","article-title":"Biomarkers of airways inflammation in patients with severe asthma in a real clinical practice","volume":"54","author":"Sergeeva","year":"2019","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.anai.2022.02.021_bib0022","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.anai.2015.10.027","article-title":"Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma","volume":"116","author":"Tran","year":"2016","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"10.1016\/j.anai.2022.02.021_bib0023","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.jaci.2016.04.007","article-title":"Role of IgE in autoimmunity","volume":"137","author":"Sanjuan","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2022.02.021_bib0024","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.rmed.2019.06.004","article-title":"Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility","volume":"154","author":"Humbert","year":"2019","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.anai.2022.02.021_bib0025","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.anai.2018.01.030","article-title":"Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma","volume":"120","author":"Chipps","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.anai.2022.02.021_bib0026","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.alit.2018.11.001","article-title":"Airway innate lymphoid cells in the induction and regulation of allergy","volume":"68","author":"Doherty","year":"2019","journal-title":"Allergol Int"},{"issue":"3","key":"10.1016\/j.anai.2022.02.021_bib0027","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1067\/mai.2000.109172","article-title":"IL-9 expression by human eosinophils: regulation by IL-1beta and TNF-alpha","volume":"106","author":"Gounni","year":"2000","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2022.02.021_bib0028","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.3389\/fphar.2019.01387","article-title":"The intriguing role of interleukin 13 in the pathophysiology of asthma","volume":"10","author":"Marone","year":"2019","journal-title":"Front Pharmacol"},{"issue":"21","key":"10.1016\/j.anai.2022.02.021_bib0029","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21217930","article-title":"Dendritic cells: critical regulators of allergic asthma","volume":"21","author":"Morianos","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.anai.2022.02.021_bib0030","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02250-2018","article-title":"The interleukin-13 paradox in asthma: effective biology, ineffective biologicals","volume":"53","author":"Nair","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.anai.2022.02.021_bib0031","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/879783","article-title":"Cellular mechanisms underlying eosinophilic and neutrophilic airway inflammation in asthma","volume":"2015","author":"Pelaia","year":"2015","journal-title":"Mediators Inflamm"},{"issue":"5","key":"10.1016\/j.anai.2022.02.021_bib0032","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1183\/09031936.00017707","article-title":"Mast cell regulation of airway smooth muscle function in asthma","volume":"29","author":"Bradding","year":"2007","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.anai.2022.02.021_bib0033","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1164\/rccm.201611-2232PP","article-title":"Eosinophilic and noneosinophilic asthma","volume":"197","author":"Carr","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.anai.2022.02.021_bib0034","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/WOX.0b013e31817a76fb","article-title":"Basophils as key regulators of allergic inflammation and Th2-type immunity","volume":"1","author":"Gibbs","year":"2008","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.anai.2022.02.021_bib0035","first-page":"1255","volume":"12","author":"Ingbar","year":"2015"},{"issue":"3","key":"10.1016\/j.anai.2022.02.021_bib0036","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00281-019-00735-6","article-title":"The immunopathology of lung fibrosis: amphiregulin-producing pathogenic memory T helper-2 cells control the airway fibrotic responses by inducing eosinophils to secrete osteopontin","volume":"41","author":"Hirahara","year":"2019","journal-title":"Semin Immunopathol"},{"issue":"6","key":"10.1016\/j.anai.2022.02.021_bib0037","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.coi.2007.07.021","article-title":"The role of eosinophils in airway tissue remodelling in asthma","volume":"19","author":"Kariyawasam","year":"2007","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2022.02.021_bib0038","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1183\/09031936.00017810","article-title":"Osteopontin expression and relation to disease severity in human asthma","volume":"37","author":"Samitas","year":"2011","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.anai.2022.02.021_bib0039","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1080\/07853890701449354","article-title":"Triggers of IgE class switching and allergy development","volume":"39","author":"Poulsen","year":"2007","journal-title":"Ann Med"},{"issue":"10221","key":"10.1016\/j.anai.2022.02.021_bib0040","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0140-6736(19)33005-3","article-title":"Intersection of biology and therapeutics: type 2 targeted therapeutics for adult asthma","volume":"395","author":"Peters","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.anai.2022.02.021_bib0041","unstructured":"US Food and Drug Administration. Xolair (omalizumab) highlights of prescribing information. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/103976s5225lbl.pdf. Accessed January 20, 2021."},{"issue":"10","key":"10.1016\/j.anai.2022.02.021_bib0042","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1164\/rccm.201903-0599LE","article-title":"Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide, and their combination in severe asthma: a post hoc analysis","volume":"200","author":"Shrimanker","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.anai.2022.02.021_bib0043","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.jaci.2017.10.005","article-title":"Biomarkers for severe eosinophilic asthma","volume":"140","author":"Yancey","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2022.02.021_bib0044","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1007\/s12325-019-01191-2","article-title":"Ability of serum IgE concentration to predict exacerbation risk and Benralizumab efficacy for patients with severe eosinophilic asthma","volume":"37","author":"Jackson","year":"2020","journal-title":"Adv Ther"},{"issue":"4","key":"10.1016\/j.anai.2022.02.021_bib0045","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.chest.2016.03.018","article-title":"Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts","volume":"150","author":"Corren","year":"2016","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.anai.2022.02.021_bib0046","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.anai.2020.04.011","article-title":"Blood eosinophil count group shifts and kinetics in severe eosinophilic asthma","volume":"125","author":"Lugogo","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/j.anai.2022.02.021_bib0047","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/cea.13310","article-title":"Variability of blood eosinophils in patients in a clinic for severe asthma","volume":"49","author":"Rakowski","year":"2019","journal-title":"Clin Exp Allergy"},{"issue":"2","key":"10.1016\/j.anai.2022.02.021_bib0048","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/all.13302","article-title":"Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma","volume":"73","author":"Casale","year":"2018","journal-title":"Allergy"},{"issue":"8","key":"10.1016\/j.anai.2022.02.021_bib0049","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study","volume":"187","author":"Hanania","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.anai.2022.02.021_bib0050","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02523-2017","article-title":"Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study","volume":"51","author":"Humbert","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.anai.2022.02.021_bib0051","doi-asserted-by":"crossref","unstructured":"Holguin F, Cardet JC, Chung KF, Diver S, Ferreira DS, Fitzpatrick A, et al. Management of severe asthma: a European Respiratory Society\/American Thoracic Society guideline.2020;55(1):1900588.","DOI":"10.1183\/13993003.00588-2019"},{"issue":"26","key":"10.1016\/j.anai.2022.02.021_bib0052","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.anai.2022.02.021_bib0053","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/j.jaip.2021.01.008","article-title":"The relationship between Feno and effectiveness of mepolizumab and benralizumab in severe eosinophilic asthma","volume":"9","author":"Hearn","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.anai.2022.02.021_bib0054","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jaip.2020.09.014","article-title":"Dupilumab improves asthma control and lung function in patients with insufficient outcome during previous antibody therapy","volume":"9","author":"M\u00fcmmler","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10","key":"10.1016\/j.anai.2022.02.021_bib0055","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S2213-2600(21)00124-7","article-title":"Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis","volume":"9","author":"Busse","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.anai.2022.02.021_bib0056","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jaip.2020.09.051","article-title":"The prevalence of subtypes of type 2 inflammation in an unselected population of patients with severe asthma","volume":"9","author":"Fr\u00f8ssing","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2022.02.021_bib0057","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jaci.2019.08.031","article-title":"Investigation of the relationship between IL-6 and type 2 biomarkers in patients with severe asthma","volume":"145","author":"Li","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2022.02.021_bib0058","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12967-017-1264-y","article-title":"Proteomic analysis of sputum reveals novel biomarkers for various presentations of asthma","volume":"15","author":"Cao","year":"2017","journal-title":"J Transl Med"},{"issue":"2","key":"10.1016\/j.anai.2022.02.021_bib0059","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/thoraxjnl-2021-217325","article-title":"Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide","volume":"77","author":"Couillard","year":"2022","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.anai.2022.02.021_bib0060","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S2213-2600(20)30397-0","article-title":"Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial","volume":"9","author":"Heaney","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"7","key":"10.1016\/j.anai.2022.02.021_bib0061","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1164\/rccm.201909-1813OC","article-title":"Evidence for exacerbation-prone asthma and predictive biomarkers of exacerbation frequency","volume":"202","author":"Peters","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.anai.2022.02.021_bib0062","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1183\/13993003.02198-2015","article-title":"Comorbidities and elevated IL-6 associate with negative outcome in adult-onset asthma","volume":"48","author":"Ilmarinen","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.anai.2022.02.021_bib0063","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1465-9921-11-28","article-title":"Elevation of IL-6 in the allergic asthmatic airway is independent of inflammation but associates with loss of central airway function","volume":"11","author":"Neveu","year":"2010","journal-title":"Respir Res"},{"issue":"7","key":"10.1016\/j.anai.2022.02.021_bib0064","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1016\/j.jaip.2021.02.047","article-title":"The association of plasma IL-6 with measures of asthma morbidity in a moderate-severe pediatric cohort aged 6-18 years","volume":"9","author":"Permaul","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"11","key":"10.1016\/j.anai.2022.02.021_bib0065","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/s41590-020-0777-3","article-title":"A regulatory T cell Notch4-GDF15 axis licenses tissue inflammation in asthma","volume":"21","author":"Harb","year":"2020","journal-title":"Nat Immunol"},{"issue":"9","key":"10.1016\/j.anai.2022.02.021_bib0066","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/nm.4147","article-title":"An asthma-associated IL4R variant exacerbates airway inflammation by promoting conversion of regulatory T cells to TH17-like cells","volume":"22","author":"Massoud","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.anai.2022.02.021_bib0067","unstructured":"National Library of Medicine. Investigating dupilumab's effect in asthma by genotype (IDEA). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03694158. Accessed July 12, 2021."},{"key":"10.1016\/j.anai.2022.02.021_bib0068","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.aca.2018.09.035","article-title":"El-Aneed A. Quantitative determination of potential urine biomarkers of respiratory illnesses using new targeted metabolomic approach","volume":"1047","author":"Khamis","year":"2019","journal-title":"Anal chim acta"},{"issue":"3","key":"10.1016\/j.anai.2022.02.021_bib0069","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jaci.2015.05.022","article-title":"Metabolomic profiling of asthma and chronic obstructive pulmonary disease: a pilot study differentiating diseases","volume":"136","author":"Adamko","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.anai.2022.02.021_bib0070","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/nri.2017.95","article-title":"Functions of tissue-resident eosinophils","volume":"17","author":"Weller","year":"2017","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/j.anai.2022.02.021_bib0071","doi-asserted-by":"crossref","first-page":"132","DOI":"10.21037\/atm.2020.02.30","article-title":"The application of proteomics in the diagnosis and treatment of bronchial asthma","volume":"8","author":"Xu","year":"2020","journal-title":"Ann Transl Med"},{"issue":"1","key":"10.1016\/j.anai.2022.02.021_bib0072","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2019.100095","article-title":"Plasma galectin-3 and urine proteomics predict FEV 1 improvement in omalizumab-treated patients with severe allergic asthma: results from the PROXIMA sub-study","volume":"13","author":"Riccio","year":"2020","journal-title":"World Allergy Organ J"},{"issue":"1","key":"10.1016\/j.anai.2022.02.021_bib0073","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2016.11.009","article-title":"Using imaging as a biomarker for asthma","volume":"139","author":"Trivedi","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2022.02.021_bib0074","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/13645706.2019.1575882","article-title":"Introduction to artificial intelligence in medicine","volume":"28","author":"Mintz","year":"2019","journal-title":"Minim Invasive Ther Allied Technol"},{"key":"10.1016\/j.anai.2022.02.021_bib0075","article-title":"Diagnosis of asthma based on routine blood biomarkers using machine learning","volume":"2020","author":"Zhan","year":"2020","journal-title":"Comp Intell Neurosci"},{"issue":"5","key":"10.1016\/j.anai.2022.02.021_bib0076","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S0091-6749(05)80181-2","article-title":"Immediate skin test reactivity to Food and Drug Administration-approved standardized extracts","volume":"86","author":"Adinoff","year":"1990","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2022.02.021_bib0077","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2019.100080","article-title":"IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper","volume":"13","author":"Ansotegui","year":"2020","journal-title":"World Allergy Organ J"},{"issue":"6","key":"10.1016\/j.anai.2022.02.021_bib0078","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/j.1398-9995.1998.tb03937.x","article-title":"Current allergic asthma and rhinitis: diagnostic efficiency of three commonly used atopic markers (IgE, skin prick tests, and Phadiatop). Results from 8329 randomized adults from the SAPALDIA Study. Swiss Study on Air Pollution and Lung Diseases in Adults","volume":"53","author":"Tschopp","year":"1998","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.anai.2022.02.021_bib0079","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1067\/mai.2003.1595","article-title":"Allergic and nonallergic forms of atopic diseases","volume":"112","author":"Novak","year":"2003","journal-title":"J Allergy Clin Immunol"},{"issue":"9842","key":"10.1016\/j.anai.2022.02.021_bib0080","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.anai.2022.02.021_bib0081","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.chest.2016.03.032","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study","volume":"150","author":"Bjermer","year":"2016","journal-title":"Chest"},{"issue":"25","key":"10.1016\/j.anai.2022.02.021_bib0082","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of Benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.anai.2022.02.021_bib0083","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jaci.2007.11.026","article-title":"Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy","volume":"121","author":"Corren","year":"2008","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2022.02.021_bib0084","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1113\/jphysiol.1956.sp005600","article-title":"Normal variation in the count of circulating eosinophils in man","volume":"133","author":"Acland","year":"1956","journal-title":"J Physiol"},{"issue":"3","key":"10.1016\/j.anai.2022.02.021_bib0085","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jaip.2020.10.033","article-title":"Variability in blood eosinophil counts in patients with eosinophilic asthma","volume":"9","author":"Corren","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.anai.2022.02.021_bib0086","doi-asserted-by":"crossref","first-page":"173","DOI":"10.4103\/1817-1737.56009","article-title":"Exhaled nitric oxide in diagnosis and management of respiratory diseases","volume":"4","author":"Abba","year":"2009","journal-title":"Ann Thorac Med"},{"issue":"1","key":"10.1016\/j.anai.2022.02.021_bib0087","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12931-019-1056-4","article-title":"Oral corticosteroid dose changes and impact on peripheral blood eosinophil counts in patients with severe eosinophilic asthma: a post hoc analysis","volume":"20","author":"Prazma","year":"2019","journal-title":"Respir Res"},{"issue":"5","key":"10.1016\/j.anai.2022.02.021_bib0088","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01874-2019","article-title":"Blood eosinophil count in the general population: typical values and potential confounders","volume":"55","author":"Hartl","year":"2020","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.anai.2022.02.021_bib0089","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/cea.13841","article-title":"Clinical evaluation of type 2 disease status in a real-world population of difficult to manage asthma using historic electronic healthcare records of blood eosinophil counts","volume":"51","author":"Azim","year":"2021","journal-title":"Clin Exp Allergy"},{"issue":"6","key":"10.1016\/j.anai.2022.02.021_bib0090","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jaip.2014.06.005","article-title":"High blood eosinophil count is a risk factor for future asthma exacerbations in adult persistent asthma","volume":"2","author":"Zeiger","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.anai.2022.02.021_bib0091","doi-asserted-by":"crossref","first-page":"375","DOI":"10.4168\/aair.2021.13.3.375","article-title":"Biomarkers for severe asthma: lessons from longitudinal cohort studies","volume":"13","author":"Lee","year":"2021","journal-title":"Allergy Asthma Immunol Res"},{"issue":"19","key":"10.1016\/j.anai.2022.02.021_bib0092","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.anai.2022.02.021_bib0093","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jaci.2015.11.020","article-title":"Multidimensional endotyping in patients with severe asthma reveals inflammatory heterogeneity in matrix metalloproteinases and chitinase 3-like protein 1","volume":"138","author":"Hinks","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2022.02.021_bib0094","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ccm.2018.10.016","article-title":"Three major efforts to phenotype asthma: severe asthma research program, asthma disease endotyping for personalized therapeutics, and unbiased biomarkers for the prediction of respiratory disease outcome","volume":"40","author":"Silkoff","year":"2019","journal-title":"Clin Chest Med"},{"issue":"2","key":"10.1016\/j.anai.2022.02.021_bib0095","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jaip.2019.11.008","article-title":"Allergic endotypes and phenotypes of asthma","volume":"8","author":"Akar-Ghibril","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2022.02.021_bib0096","doi-asserted-by":"crossref","unstructured":"Crisford H, Sapey E, Rogers GB, Taylor S, Nagakumar P, Lokwani R, et al. Neutrophils in asthma: the good, the bad and the bacteria. Thorax. 2021;76(8):835\u2013844.","DOI":"10.1136\/thoraxjnl-2020-215986"},{"key":"10.1016\/j.anai.2022.02.021_bib0097","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3389\/fmed.2017.00103","article-title":"Bidirectional mast cell-eosinophil interactions in inflammatory disorders and cancer","volume":"4","author":"Galdiero","year":"2017","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"10.1016\/j.anai.2022.02.021_bib0098","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1164\/rccm.200906-0896OC","article-title":"Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program","volume":"181","author":"Moore","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.anai.2022.02.021_bib0099","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12931-016-0482-9","article-title":"Validated and longitudinally stable asthma phenotypes based on cluster analysis of the ADEPT study","volume":"17","author":"Loza","year":"2016","journal-title":"Respir Res"},{"key":"10.1016\/j.anai.2022.02.021_bib0100","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12931-015-0299-y","article-title":"Asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) longitudinal profiling study","volume":"16","author":"Silkoff","year":"2015","journal-title":"Respir Res"},{"issue":"3","key":"10.1016\/j.anai.2022.02.021_bib0101","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","article-title":"Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE","volume":"60","author":"Humbert","year":"2005","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.anai.2022.02.021_bib0102","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2022.02.021_bib0103","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1183\/09031936.01.00092101","article-title":"The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics","volume":"18","author":"Sol\u00e8r","year":"2001","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.anai.2022.02.021_bib0104","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1365-2222.2004.1916.x","article-title":"Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma","volume":"34","author":"Holgate","year":"2004","journal-title":"Clin Exp Allergy"},{"issue":"9","key":"10.1016\/j.anai.2022.02.021_bib0105","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-154-9-201105030-00002","article-title":"Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial","volume":"154","author":"Hanania","year":"2011","journal-title":"Ann Intern Med"},{"issue":"13","key":"10.1016\/j.anai.2022.02.021_bib0106","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.anai.2022.02.021_bib0107","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"13","key":"10.1016\/j.anai.2022.02.021_bib0108","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.anai.2022.02.021_bib0109","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"7","key":"10.1016\/j.anai.2022.02.021_bib0110","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1016\/j.jaip.2019.01.017","article-title":"Efficacy and safety of reslizumab in patients with severe asthma with inadequate response to omalizumab: a multicenter, open-label pilot study","volume":"7","author":"P\u00e9rez de Llano","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10056","key":"10.1016\/j.anai.2022.02.021_bib0111","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.anai.2022.02.021_bib0112","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.anai.2022.02.021_bib0113","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa2106567","article-title":"Dupilumab in children with uncontrolled moderate-to-severe asthma","volume":"385","author":"Bacharier","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.anai.2022.02.021_bib0114","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1111\/j.1398-9995.2009.02119.x","article-title":"Relationship between pretreatment specific IgE and the response to omalizumab therapy","volume":"64","author":"Wahn","year":"2009","journal-title":"Allergy"},{"issue":"7","key":"10.1016\/j.anai.2022.02.021_bib0115","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.rmed.2007.01.011","article-title":"Predicting and evaluating response to omalizumab in patients with severe allergic asthma","volume":"101","author":"Bousquet","year":"2007","journal-title":"Respir Med"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120622001703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120622001703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:29:23Z","timestamp":1761053363000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120622001703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":115,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S1081120622001703"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2022.02.021","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allergic and eosinophilic asthma in the era of biomarkers and biologics: similarities, differences and misconceptions","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2022.02.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}